Suppression of cardiac memory–related severe form of torsades de pointes by landiolol in a patient with congenital long QT syndrome type 2

Sou Otsuki, MD, PhD, Daisuke Izumi, MD, PhD, Yuki Hasegawa, MD, PhD, Nobue Yagihara, MD, PhD, Kenichi Iijima, MD, PhD, Tohru Minamino, MD, PhD

From the Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Introduction
Although earlier studies reported the benefit of antibradycardia pacing in patients with recurrent syncope or cardiac arrest, ventricular pacing without implantable cardioverter-defibrillator (ICD) implantation is associated with a significant risk of recurrent sudden cardiac arrest and death in patients with long QT syndrome (LQTS).1 Cardiac memory is usually a benign phenomenon of persistent T-wave abnormalities appearing during normal ventricular activation after a period of altered ventricular activation.2 Few case reports have suggested the proarrhythmic effect of cardiac memory in patients with congenital LQTS.3 The proarrhythmic effect of cardiac memory and the efficacy of beta-blockers in suppressing torsades de pointes (Tdp) due to cardiac memory remain unclear. We present a case of a 41-year-old patient with LQT type 2 who had cardiac memory–related Tdp that was suppressed by landiolol.

Case report
A 41-year-old woman had been experiencing episodes of syncope with remarkable QT interval prolongation since the age of 18 years (Figure 1). Her father and paternal grandmother had QT prolongation and her paternal grandmother had TdP requiring a shock from an automated external defibrillator at the age of 75 years (Supplemental Figures 1 and 2). Her paternal great-grandfather died suddenly at age 47 years. Genetic testing in the 41-year-old case patient revealed a mutation in KCNH2 (c.3103delC). The previous study identified the mutation in the cohort of patients with LQTS as pathogenic.4 Therefore she was diagnosed with LQTS type 2 (LQT2). At the age of 24 years, a single-chamber ICD was implanted for primary prevention. At that time, the dual-chamber ICD was not yet available. Although she was treated with bisoprolol (3.75 mg/day) and mexiletine (300 mg/day), she had occasional episodes of syncope and ICD shocks due to the Tdp or ventricular fibrillation during exertion. Because of increasing sinus bradycardia, the percentage of ventricular pacing increased from 70% to 100% by age 38 years. Her slight fatigue and mildly elevated brain natriuretic peptide levels were of concern, as was the percentage of ventricular pacing, and resulted in an upgrade to a dual-chamber ICD with the addition of an atrial lead, discouraging ventricular pacing. Although electrocardiography revealed atrial paced rhythm with long QT interval and T waves discordant with the QRS axis, she had no episodes of syncope or ICD therapy (QT, 480 ms; QTc, 519 ms).

Three years later she had an atrial lead fracture. The atrial lead revision was planned for 4 months later and the device reprogramed to VVI. However, after 2 months she had an appropriate shock for Tdp. Electrocardiography revealed right ventricular apical paced rhythm with markedly longer QTc than that at 2 months earlier (from 539 ms to 647 ms) and giant T waves concordant with the QRS axis (Supplemental Figure 3). Her plasma potassium (4.3 mmol/L), magnesium (2.0 mg/dL), and corrected calcium levels (2.2 mmol/L) were within their normal ranges. Her echocardiogram at the time was normal with normal systolic left ventricular function. Reimplantation of the atrial lead was not used due to the risk of Tdp. At the age of 41 years, the patient was referred to our hospital because of frequent episodes of syncope and ICD shocks (Figure 1). She was treated with bisoprolol and mexiletine, and because of the risk of ventricular fibrillation during exertion, she was referred for a referral for dual-chamber ICD with implantation of atrial lead. Due to the risk of ventricular arrhythmia, the percentage of ventricular pacing increased from 70% to 100% by age 41 years. Her slight fatigue and mildly elevated brain natriuretic peptide levels were of concern, as was the percentage of ventricular pacing, and resulted in an upgrade to a dual-chamber ICD with the addition of an atrial lead, discouraging ventricular pacing. Although electrocardiography revealed atrial paced rhythm with long QT interval and T waves discordant with the QRS axis, she had no episodes of syncope or ICD therapy (QT, 480 ms; QTc, 519 ms).

KEY TEACHING POINTS
- Cardiac memory in changing pacing mode may cause marked longer QTc and torsades de pointes (Tdp) in patients with long QT syndrome (LQTS).
- In patients with congenital LQTS, we may have to consider atrial lead implantation for avoiding proarrhythmic effects related to ventricular pacing.
- Landiolol may be worth considering as the drug of choice for the treatment of Tdp in congenital LQTS.

KEYWORDS Cardiac memory; Long QT syndrome; Landiolol; Torsades de pointes; Ventricular pacing
(Heart Rhythm Case Reports 2020;6:407–410)

Address reprint requests and correspondence: Dr Sou Otsuki, Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachidori, Chuo-ku, Niigata 951-8510, Japan. E-mail address: tallmoca_0825@yahoo.co.jp.

2214-0271/© 2020 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
planned at 10 days after admission. Programming the device with a higher pacing rate (VVI 90 ppm) suppressed the Tdp in the interim. She underwent atrial lead reimplantation under general anesthesia with propofol and dexmedetomidine, and the pacing mode was reprogrammed to dual chamber (DDD 70 ppm) just after the procedure. Around 4 hours after the procedure, she had a Tdp electrical storm (Figure 2). The electrolytes were normal (plasma potassium level was 4.1 mmol/L, magnesium 1.7 mg/dL, and corrected calcium levels 2.2 mmol/L). Device programming with a higher pacing rate (DDD 90 ppm) and intravenous administration of magnesium sulfate failed to suppress the Tdp. Subsequently, administration of landiolol was started at 3 mg/kg/min and increased to 6 mg/kg/min, which completely suppressed the Tdp without changing the QT interval (Figure 3A). Around 1 week later, she continued the bisoprolol therapy (3.75 mg/day) with tapering and discontinuation of the landiolol therapy, and had no further episodes of Tdp. After 9 months without ventricular pacing, the giant negative T waves returned to their stationary state (Figure 3B).

**Discussion**

Although cardiac memory is usually a benign phenomenon, this case suggests that caution should be used when changing pacing mode in patients with LQTS. Only 1 previous report described the proarrhythmic effect of cardiac memory in a patient with congenital LQTS. One of the ion channel changes of cardiac memory has been previously reported to be a transcriptionally induced reduction in potassium (IKr) channels. Di Cori and colleagues suggested that cardiac memory might be potentially risky in patients with a baseline IKr loss of function. Repolarization abnormalities might be revealed owing to cardiac memory after changing the pacing mode, so the effect of cardiac memory in changing the pacing mode, especially in patients with LQT2, must be considered.
Figure 2  Twelve-lead electrocardiogram obtained during the torsades de pointes electrical storm, after reprogramming to the DDD mode. The premature ventricular contraction on the T wave induced polymorphic ventricular tachycardia.

Figure 3  Twelve-lead electrocardiograms in the DDD mode: A: after administration of landiolol; B: 9 months after the torsades de pointes (Tdp) storm. Administration of landiolol had no effect to the prolongation of the QTc interval, but suppressed the Tdp electrical storm.
This is the first reported case of suppression of cardiac memory–related Tdp with landiolol in a patient with LQT2. Beta-blockers have been shown to either decrease or prevent an increase in transmural dispersion of repolarization in response to strong sympathetic stimulation, a mechanism that contributes to its antiarrhythmic effect. Although only few reports have indicated the efficacy of landiolol for Tdp in congenital LQTS, beta-blockers have a preventive effect on Tdp in patients with congenital LQT1 or LQT2. Moreover, a previous study suggested that low-dose landiolol inhibits Ca\(^{2+}\) leakage through the ryanodine receptor (RyR2) by selectively suppressing RyR2 phosphorylation. Landiolol might be superior to other beta-blockers owing to its direct effects on RyR2 and diastolic Ca\(^{2+}\) leakage. Landiolol may be worth considering as the drug of choice for the treatment of Tdp in congenital LQTS, especially in the acute phase, because landiolol is ultra-short-acting, unlike other beta-blockers such as propranolol.

Eighteen months after the atrial lead reimplantation, the patient required ventricular lead reimplantation owing to lead fracture. Under the same conditions as the previous procedure of atrial lead implantation (ie, general anesthesia with propofol and dexmedetomidine, oral drugs, and baseline lower pacing rate), she underwent the ventricular lead implantation. However, the QT interval was stable during the procedure during the atrial pacing. This case is important because it demonstrates the effect of cardiac memory through the difference in clinical course between the atrial and ventricular lead reimplantations.

Several studies have reported not all beta-blockers are equal for risk reduction in long QT. For LQT2, nadolol was reported to show superior efficacy. Therefore, the use of nadolol in this patient from the onset may have made the disease less malignant.

Acknowledgments
The authors thank Editage (www.editage.com) for English language editing.

Appendix

Supplementary data
Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hrcr.2020.03.013.

References
1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death; A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2018; 138:e272–e391.
2. Rosso R, Adler A, Strasberg B, et al. Long QT syndrome complicating atrioventricular block arrhythmogenic effects of cardiac memory. Circ Arrhythm Electrophysiol 2014;7:1129–1135.
3. Di Cori A, Zacchelli G, Romano S, Bongiorni MG. Prolargrhythmic effect of pacing mode reprogramming in a patient with a congenital long-QT syndrome. J Cardiovasc Electrophysiol 2013;24:1304–1305.
4. Kapplinger JD, Tester DJ, Salisbury BA, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009; 6(9):1297–1303.
5. Obreztchikova MN, Patberg KW, Plotnikov AN, et al. I(Kr) contributes to the altered ventricular repolarization that determines long-term cardiac memory. Cardiovasc Res 2006;71:88–96.
6. Shimizu W, Tanabe Y, Aiba T, et al. Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2002;39:1984–1991.
7. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACEs, and AEPC in June 2013. Heart Rhythm 2013;10:1932–1963.
8. Kobayashi S, Susa T, Ishiguchi H, et al. A low-dose beta1-blocker in combination with milrinone improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition of milrinone-induced diastolic Ca2+ leakage from the sarcoplasmic reticulum. PLoS One 2015;10:e0114314.
9. Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012; 60:2092–2099.
10. Abu-Zeitine A, Peterson DR, Polonsky B, et al. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol 2014; 64:1352–1358.